AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026
WATERTOWN, Mass. and DRESDEN, Germany, June 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, today announced that data from the completed Phase 1a portion of the RevSTAR-123 study, evaluating AvenCell's...
WATERTOWN, Mass. and DRESDEN, Germany, June 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, today announced that data from the completed Phase 1a portion of the RevSTAR-123 study, evaluating AvenCell's...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.